What research findings exist on Ipamorelin in GH secretion, bone growth, and body composition?
Ipamorelin shows antagonistic effects on the decline of certain muscle strength and bone formation. Other studies report: increased bone mineral content and bone volume, providing evidence for GH-related bone metabolism.[1] ↗ [2] ↗
Currently, 4 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2001 · PMID 11735244 | Adult female rats; glucocorticoid-related catabolic model, 3 months | Ipamorelin shows antagonistic effects on the decline of certain muscle strength and bone formation. | Specific hormone injury model; cannot infer muscle gain or height increase in healthy adults. |
| 2000 · PMID 10828840 | Adult female rats; 12-week Ipamorelin or GHRP-6 intervention | Bone mineral content and bone volume increase, providing evidence for GH-related bone metabolism. | Weight-adjusted total bone mineral content ratio and volumetric bone density did not improve; not confirmed as human osteoporosis. |
| 1999 · PMID 10496658 | Healthy male volunteers; Ipamorelin dose-escalation infusion pharmacokinetic/pharmacodynamic study | GH release was observed at all study doses, providing human physiological evidence for its GH secretion mechanism. | Only indicates short-term hormone response; does not prove muscle growth, height increase, or anti-aging; 1999 basic research. |
| 1999 · PMID 10373343 | Adult female rats; 15 days | Longitudinal bone growth rate increased in a dose-dependent manner. | 1999; cannot be promoted as adult height increase or human muscle growth. |
References
What findings are there on hormone-related muscle strength and bone formation studies?
Ipamorelin shows antagonistic effects on the decline of certain muscle strength and bone formation.[1] ↗
Adult female rats; glucocorticoid-related catabolic model, 3 months
Specific hormone injury model; cannot infer muscle gain or height increase in healthy adults.
View the Article Title and Full Citation＋
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.
Growth Hormone & IGF Research: official journal of the Growth Hormone Research Society and the International IGF Research Society · Volume/Issue Year 2001
First published 2001-10-01 · PMID 11735244
DOI 10.1054/ghir.2001.0239
What does an increase in bone mineral content mean?
Bone mineral content and bone volume increase, providing evidence for GH-related bone metabolism.[2] ↗
Adult female rats; 12-week Ipamorelin or GHRP-6 intervention
Weight-adjusted total bone mineral content ratio and volumetric bone density did not improve; not confirmed as human osteoporosis.
View the Article Title and Full Citation＋
The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.
The Journal of Endocrinology · Volume, Issue, Year 2000
First published 2000-06-01 · PMID 10828840
DOI 10.1677/joe.0.1650569
What does short-term GH release study in humans indicate?
GH release was observed at all study doses, providing human physiological evidence for its GH secretion mechanism.[3] ↗
Healthy male volunteers; Ipamorelin dose-escalation infusion pharmacokinetic/pharmacodynamic study
Only indicates short-term hormone response; does not prove muscle growth, height increase, or anti-aging; 1999 basic research.
View the Article Title and Full Citation＋
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Pharmaceutical Research · Volume and Issue Year 1999
First published 1999-09-01 · PMID 10496658
DOI 10.1023/a:1018955126402
What does the longitudinal bone growth study in rats show?
Longitudinal bone growth rate increased in a dose-dependent manner.[4] ↗
Adult female rats; 15 days
1999; cannot be promoted as adult height increase or human muscle growth.
View the Article Title and Full Citation＋
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
Growth Hormone & IGF Research: official journal of the Growth Hormone Research Society and the International IGF Research Society · Volume/Issue Year 1999
First published 1999-04-01 · PMID 10373343
DOI 10.1054/ghir.1999.9998
Common issues and corresponding evidence
What research findings exist on Ipamorelin in GH secretion, bone growth, and body composition?＋
Ipamorelin shows antagonistic effects on the decline of certain muscle strength and bone formation. Other studies report: increased bone mineral content and bone volume, providing evidence for GH-related bone metabolism.[1] ↗ [2] ↗
Ipamorelin stimulates GH; can it directly be assumed to increase muscle or height?＋
Not possible. Short-term human trials record GH release, and animal studies observe bone growth and metabolism; these endpoints differ from adult height increase, muscle strength, or long-term body composition benefits.[3] ↗ [4] ↗ [2] ↗
Ipamorelin—these conclusions apply to which study populations?＋
Adult female rats; glucocorticoid-related catabolic model, 3 months; adult female rats; 12-week Ipamorelin or GHRP-6 intervention; healthy male volunteers; Ipamorelin dose-escalation infusion pharmacokinetic/pharmacodynamic study. Specific hormone injury model; cannot infer muscle gain or height increase in healthy adults.[1] ↗ [2] ↗ [3] ↗
Ipamorelin
Return to catalog specifications and batch file verification entry.
